Ligand id: 7990

Name: atezolizumab

1. Irving B, Chiu H, Maecker H, Mariathasan S, Lehar SM, Wu Y, Cheung J. (2012)
Anti-PD-L1 antibodies, compositions and articles of manufacture.
Patent number: US8217149. Assignee: Genentech, Inc.. Priority date: 09/12/2008. Publication date: 10/07/2012.
2. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017)
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
Sci Rep, 7 (1): 5532. [PMID:28717238]
3. Pardoll DM. (2012)
The blockade of immune checkpoints in cancer immunotherapy.
Nat. Rev. Cancer, 12 (4): 252-64. [PMID:22437870]
4. Topalian SL, Drake CG, Pardoll DM. (2015)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Cancer Cell, 27 (4): 450-61. [PMID:25858804]